2011-10-13T10:44:00-05:00 2010-12-31 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650 NORTH BETHESDA MD 208142930 990 2010-01-01 830431851 PATH VACCINE SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 ERIC WALKER 2062853500 2011-10-13 1 3019519090 2010 2016-03-07 17:11:31Z CHRISTOPHER J ELIAS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 32789331 0 X WWW.PATH.ORG X 2006 WA THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-INCOME COUNTRIES BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE IN COUNTRIES THAT NEED THEM MOST. FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT. 7 3 0 0 0 0 31083199 32724826 1500 3500 174229 53857 22681 7148 31281609 32789331 31772234 30660682 0 0 0 0 0 0 0 3230106 5260313 35002340 35920995 -3720731 -3131664 152797602 151102797 3346736 4781234 149450866 146321563 X PVS WORKS WITH PARTNERS TO DEVELOP NEW VACCINES BY PROVIDING FUNDING AND EXPERTISE IN NONCLINICAL DEVELOPMENT, MANUFACTURING, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-INCOME COUNTRIES. IN RETURN, PARTNERS AGREE TO TERMS THAT WILL HELP ENSURE THAT THE PRODUCTS ARE AFFORDABLE AND AVAILABLE IN DEVELOPING COUNTRIES. 0 0 35920995 30660682 10648 PVS WORKS TO PREVENT DEATHS FROM PNEUMONIA, INFLUENZA, AND DIARRHEA AMONG CHILDREN AROUND THE WORLD BY ACCELERATING VACCINE DEVELOPMENT. IN PARTNERSHIP WITH MULTIPLE PUBLIC AND PRIVATE GROUPS, PVS DEVELOPS SAFE, EFFICACIOUS, AND AFFORDABLE VACCINES AGAINST PNEUMOCOCCAL DISEASE, INFLUENZA, ROTAVIRUS, SHIGELLA, AND ENTEROTOXIGENIC ESCHERICHIA COLI. IN 2010, PVS ADVANCED RESEARCH AND DEVELOPMENT OF A NUMBER OF PROMISING PNEUMOCOCCAL VACCINE CANDIDATES AND RELATED TECHNOLOGIES. THIS WORK COVERED MULTIPLE STAGES IN THE DEVELOPMENT PROCESS, FROM PRELIMINARY RESEARCH TO PRECLINICAL DEVELOPMENT TO CLINICAL TRIALS FOR SEVERAL CANDIDATES. FOR EXAMPLE, WE SUPPORTED THE ADVANCEMENT OF AN INACTIVATED WHOLE CELL VACCINE THAT HAS SHOWN PROMISE IN PRECLINICAL TESTING THROUGH A SUCCESSFUL PRE-INVESTIGATIONAL NEW DRUG MEETING WITH THE US FOOD AND DRUG ADMINISTRATION. AND WE PREPARED TO LAUNCH A TWO-STAGE PHASE 2 CLINICAL TRIAL IN THE GAMBIA OF A VACCINE AGAINST STREPTOCOCCUS PNEUMONIAE. OUR PARTNERS INCLUDED ACADEMIC GROUPS (SUCH AS THE UNIVERSITY OF ADELAIDE, BUTANTAN INSTITUTE IN BRAZIL, UNIVERSITY OF GLASGOW, AND THE LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE), INDUSTRY PARTNERS (INCLUDING CHINA NATIONAL BIOTEC GROUP'S CHENGDU INSTITUTE OF BIOLOGICAL PRODUCTS, GENOCEA BIOSCIENCES, GLAXOSMITHKLINE BIOLOGICALS, INTERCELL AG, MUCOSIS BV, AND THE SERUM INSTITUTE OF INDIA LTD.), AND HEALTH CARE INSTITUTIONS (SUCH AS CHILDREN'S HOSPITAL BOSTON). PVS ALSO WORKED DURING 2010 TO ADVANCE DEVELOPMENT OF PROMISING NEW INFLUENZA VACCINES, FOCUSING ON NOVEL TECHNOLOGIES THAT CAN BE ACCESSIBLE, AFFORDABLE, AND AVAILABLE TO PEOPLE IN LOW-RESOURCE SETTINGS DURING INFLUENZA OUTBREAKS. HIGHLIGHTS INCLUDED ADVANCING PRECLINICAL DEVELOPMENT OF SEVERAL AVIAN LIVE ATTENUATED INFLUENZA VACCINE CANDIDATES, CONDUCTING A LANDSCAPE ANALYSIS FOR INTRANASAL DELIVERY DEVICES TO BE USED WITH THOSE VACCINE CANDIDATES, AND ENTERING INTO NEW PARTNERSHIPS TO INITIATE RESEARCH ON INFLUENZA VACCINES THAT CAN ELICIT BROAD COVERAGE ACROSS INFLUENZA STRAINS. OUR PARTNERS INCLUDED THE INSTITUTE OF EXPERIMENTAL MEDICINE IN RUSSIA, MEDICAGO INC., LENTIGEN, THE UNIVERSITY OF PITTSBURGH, AND THE INFECTIOUS DISEASE RESEARCH INSTITUTE OF SEATTLE.INFECTION WITH ROTAVIRUS IS A MAJOR CAUSE OF SEVERE DIARRHEA AND DEATH AMONG YOUNG CHILDREN IN LOW-INCOME COUNTRIES. PVS AIMS TO ACCELERATE INTRODUCTION OF SAFE, AFFORDABLE, AND EFFECTIVE ROTAVIRUS VACCINES IN THE DEVELOPING WORLD BY PROVIDING TECHNICAL AND FINANCIAL SUPPORT TO EMERGING-COUNTRY MANUFACTURERS. HIGHLIGHTS DURING 2010 INCLUDED WORKING WITH BHARAT BIOTECH INTERNATIONAL IN INDIA TO SUPPORT THE LATE-STAGE DEVELOPMENT OF A PROMISING VACCINE CANDIDATE AND PREPARE FOR PHASE 3 EFFICACY CLINICAL TRIALS; PARTNERING WITH THE SERUM INSTITUTE OF INDIA LTD. TO PREPARE FOR PHASE 3 CLINICAL TRIALS OF ANOTHER TYPE OF ROTAVIRUS VACCINE; AND PROVIDING A SHARED TECHNOLOGY PLATFORM THAT ALLOWS MANUFACTURERS OF NEW ROTAVIRUS VACCINES TO ACCESS A HOST OF NEEDED TECHNOLOGIES, TRAINING, AND TECHNICAL SUPPORT.PVS ALSO ADVANCES RESEARCH AND DEVELOPMENT OF VACCINES AGAINST THE TWO LEADING BACTERIAL CAUSES OF DIARRHEA, SHIGELLA AND ENTEROTOXIGENIC ESCHERICHIA COLI. MUCH OF THIS WORK IS DONE THROUGH PARTNERSHIPS WITH PUBLIC- AND PRIVATE-SECTOR ORGANIZATIONS. KEY ACTIVITIES IN 2010 INCLUDED SIGNING SEVEN NEW PARTNERSHIP AGREEMENTS FOR RESEARCH, DEVELOPMENT, AND TESTING OF VACCINE CANDIDATES AND RELATED TECHNOLOGY; COMPLETING A PHASE 2B CHALLENGE STUDY OF ONE VACCINE CANDIDATE AND HELPING TO SUPPORT THE LAUNCH OF PHASE 1 TRIALS OF TWO OTHER VACCINE CANDIDATES; AND FUNDING AND HOSTING VACCINE WORKSHOPS ON DIARRHEAL DISEASE IN VIETNAM AND THE USE OF ORAL VACCINES IN INFANTS. OUR PARTNERS INCLUDED THE INTERNATIONAL VACCINE INITIATIVE, OKLAHOMA STATE UNIVERSITY, THE US NAVAL MEDICAL RESEARCH CENTER, MUCOSIS B.V., THE UNIVERSITY OF MARYLAND, BALTIMORE, AND THE WALTER REED ARMY INSTITUTE OF RESEARCH. 35920995 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 3 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 WA X X MARLOW KEE CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 CHRISTOPHER J ELIAS 1.00 X X 0 516893 39394 JACQUELINE D SHERRIS 1.00 X X 0 237944 28352 ERIC G WALKER 1.00 X X 0 224097 35303 DAN LASTER 1.00 X 0 208322 26579 N REGINA RABINOVICH 1.00 X 0 0 0 DOUGLAS HOLTZMAN 1.00 X 0 0 0 TOM BREWER 1.00 X 0 0 0 DAVID ALLI 1.00 X 0 138991 24912 0 1326247 154540 0 0 1 0 0 32724826 32724826 HONORARIA 900099 3500 3500 3500 53857 53857 OTHER REIMBURSEMENT 900099 7148 7148 7148 32789331 10648 0 53857 16898669 16898669 13762013 13762013 60024 60024 1010 1010 7837 7837 378733 378733 15491 15491 244341 244341 4769 4769 1358878 1358878 148536 148536 12433 12433 SUBCONTRACTS 2876274 2876274 LAB SUPPLIES 67196 67196 TAXES 55118 55118 EQUIPMENT R&M & PROCURE 27237 27237 PROF. DUES/MEMBERSHIPS 2582 2582 -146 -146 35920995 35920995 0 0 X 49427914 10065380 103363592 80022019 6096 78013 60937385 152797602 151102797 3346736 4781234 3346736 4781234 X 149450866 146321563 149450866 146321563 152797602 151102797 X -3131664 2361 X 0 1 1 X 0 X X X 0 0 0 PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH 911157127 BOX 7 1 35920995 1 35920995 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 EAST ASIA AND THE PACIFIC 0 5 PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 259302 EAST ASIA AND THE PACIFIC GRANTS 1298564 EUROPE 0 3 PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 780323 EUROPE GRANTS 4420999 MIDDLE EAST 0 0 PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 210 NORTH AMERICA 0 0 PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 43489 NORTH AMERICA GRANTS 300000 RUSSIA AND THE NEWLY INDEPENDENT STATES PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 5410 RUSSIA AND THE NEWLY INDEPENDENT STATES GRANTS 716500 SOUTH AMERICA PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 25 SOUTH AMERICA GRANTS 440595 SOUTH ASIA 3 PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 425475 SOUTH ASIA GRANTS 5184007 SUB-SAHARAN AFRICA 1 PROGRAM SRVCS VACCINES AND IMMUNIZATIONS 155714 SUB-SAHARAN AFRICA GRANTS 1401348 8 4 12 7108297 8323664 15431961 X EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 21084 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 21000 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 383460 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 60000 SOUTH ASIA VACCINES AND IMMUNIZATIONS 196244 EUROPE VACCINES AND IMMUNIZATIONS 22574 EUROPE VACCINES AND IMMUNIZATIONS 427920 SOUTH AMERICA VACCINES AND IMMUNIZATIONS 440595 EUROPE VACCINES AND IMMUNIZATIONS 1434569 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 650000 SOUTH ASIA VACCINES AND IMMUNIZATIONS 60000 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 13561 NORTH AMERICA VACCINES AND IMMUNIZATIONS 300000 SUB-SAHARAN AFRICA VACCINES AND IMMUNIZATIONS 960664 EUROPE VACCINES AND IMMUNIZATIONS 338835 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 9036 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 12371 EUROPE VACCINES AND IMMUNIZATIONS 37500 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 28052 RUSSIA AND THE NEWLY INDEPENDENT STATES VACCINES AND IMMUNIZATIONS 716500 SOUTH ASIA VACCINES AND IMMUNIZATIONS 3500000 SOUTH ASIA VACCINES AND IMMUNIZATIONS 12391 SOUTH ASIA VACCINES AND IMMUNIZATIONS 1415372 EUROPE VACCINES AND IMMUNIZATIONS 800000 SUB-SAHARAN AFRICA VACCINES AND IMMUNIZATIONS 440684 EUROPE VACCINES AND IMMUNIZATIONS 65181 EAST ASIA & THE PACIFIC VACCINES AND IMMUNIZATIONS 100000 EUROPE VACCINES AND IMMUNIZATIONS 394421 EUROPE VACCINES AND IMMUNIZATIONS 900000 19 10 0 0 0 0 0 0 PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: SCHEDULE F, PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 ALBERT B SABIN INSTITUTE INC 2000 PENNSYLVANIA AVENUE NW WASHINGTON DC 20006 061389829 501(C)(3) 16000 VACCINES AND IMMUNIZATIONS BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY 340 PANAMA ST STANFORD CA 94305 941156365 501(C)(3) 15446 VACCINES AND IMMUNIZATIONS CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 75000 VACCINES AND IMMUNIZATIONS CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI OH 45229 310833936 501(C)(3) 23533 VACCINES AND IMMUNIZATIONS EMMES CORPORATION THE 401 NORTH WASHINGTON STREET SUITE 700 ROCKVILLE MD 20850 541058268 N/A 95686 VACCINES AND IMMUNIZATIONS FOOD & DRUG ADMINISTRATION (FDA) DHHS/FDA/CDRH/OST/DMMS BETHESDA MD 20892 530196965 GOVERNMENT 380000 VACCINES AND IMMUNIZATIONS GENOCEA BIOSCIENCES INC 161 FIRST STREET CAMBRIDGE MA 02139 510596811 N/A 638804 VACCINES AND IMMUNIZATIONS INC RESEARCH INC 4700 FALLS OF NEUSE SUITE 400 RALEIGH NC 27609 330723120 N/A 9143 VACCINES AND IMMUNIZATIONS INFECTIOUS DISEASE RESEARCH INSTITUTE (IDRI) 1124 COLUMBIA STREET SUITE 400 SEATTLE WA 98104 911608978 501(C)(3) 500000 VACCINES AND IMMUNIZATIONS INTEGRESS MEETINGS AND EVENTS 2 RAVINIA DRIVE SUITE 605 ATLANTA GA 30346 582526963 N/A 40000 VACCINES AND IMMUNIZATIONS LENTIGEN CORPORATION 910 CLOPPER ROAD SUITE 200 GAITHERSBURG MD 20878 861131845 N/A 1467612 VACCINES AND IMMUNIZATIONS NEUGENESIS CORPORATION 863 MITTEN ROAD SUITE C BURLINGAME CA 94010 990299143 N/A 186571 VACCINES AND IMMUNIZATIONS PITTSBURGH UNIVERSITY OF OFFICE OF RESEARCH 123 UNIVERSITY PLACE LOWER LOBBY PITTSBURGH PA 15213 250965591 501(C)(3) 400000 VACCINES AND IMMUNIZATIONS PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH 2201 WESTLAKE AVENUE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 10280497 VACCINES AND IMMUNIZATIONS PURDUE UNIVERSITY 610 PURDUE MALL WEST LAFAYETTE IN 47907 356002041 501(C)(3) 43390 VACCINES AND IMMUNIZATIONS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 35294 636005396 501(C)(3) 310000 VACCINES AND IMMUNIZATIONS THE JOHNS HOPKINS UNIVERSITY APPLIED PHYSICS LABORATORY JOHNS HOPKINS ROAD LAUREL MD 20707 520595110 501(C)(3) 250000 VACCINES AND IMMUNIZATIONS UNIVERSITY OF KANSAS CENTER FOR RESEARCH INC 2385 IRVING HILL ROAD LAWRENCE KS 66045 480680117 501(C)(3) 165000 VACCINES AND IMMUNIZATIONS UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 21203 526002033 501(C)(3) 406665 VACCINES AND IMMUNIZATIONS UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER THE 1000 SL YOUNG OKLAHOMA CITY OK 73104 736017987 501(C)(3) 84661 VACCINES AND IMMUNIZATIONS WALTER REED ARMY INSTITUTE OF RESEARCH (WRAIR) 503 ROBERT GRANT AVENUE SILVER SPRING MD 10910 520664528 GOVERNMENT 1507444 VACCINES AND IMMUNIZATIONS 15 6 PROCEDURE FOR MONITORING GRANTS IN THE U.S.: PART I, LINE 2: SCHEDULE I, PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 CHRISTOPHER J ELIAS 0 399446 0 117147 0 300 0 28828 0 10566 0 556287 0 0 JACQUELINE D SHERRIS 0 237644 0 0 0 300 0 26569 0 1783 0 266296 0 0 ERIC G WALKER 0 223636 0 0 0 461 0 24545 0 10758 0 259400 0 0 DAN LASTER 0 208322 0 0 0 0 0 16666 0 9913 0 234901 0 0 DAVID ALLI 0 138991 0 0 0 0 0 16679 0 8233 0 163903 0 0 FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY ACCOUNTING SERVICES STAFF. THE FORM 990 WAS REVIEWED BY SENIOR MANAGEMENT. A COPY OF THE DRAFT FORM 990 WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRESIDENT AND CEO SIGNED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS, PVS MANAGEMENT, AND ALL STAFF ABOVE A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. EACH YEAR AT THE ANNUAL MEETING, THE GENERAL COUNSEL INFORMS BOARD MEMBERS OF THE REQUIREMENT TO DISCLOSE ANY CONFLICT OF INTEREST. EACH BOARD MEMBER COMPLETES AND SIGNS A CONFLICT FORM ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 PVS'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE UPON REQUEST. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED GAINS ON INVESTMENTS: 2,361. FORM 990, PART VII, SECTION A, COLUMN (B): CHRISTOPHER J. ELIAS, CHAIR, DEVOTES 40 HOURS PER WEEK TO THE PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH (PATH), AS ITS PRESIDENT AND CEO. JACQUELINE D. SHERRIS, VICE CHAIR, DEVOTES 40 HOURS PER WEEK TO PATH AS ITS VICE PRESIDENT OF GLOBAL PROGRAMS. ERIC G. WALKER, TREASURER, DEVOTES 40 HOURS PER WEEK TO PATH AS ITS VICE PRESIDENT OF CORPORATE SERVICES. DAN LASTER, DIRECTOR, DEVOTES 40 HOURS PER WEEK TO PATH AS ITS GENERAL COUNSEL. DAVID ALLI, BOARD SECRETARY, DEVOTES 40 HOURS PER WEEK TO PATH AS ITS DIRECTOR OF ADMINISTRATION AND FINANCE FOR VACCINE DEVELOPMENT. PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98109 911157127 GLOBAL HEALTH WA 501(C)(3) BOX 7 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0